These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 10563597)
21. Neurologist adherence to clinical practice guidelines and costs in patients with newly diagnosed and chronic epilepsy in Germany. Strzelczyk A; Bergmann A; Biermann V; Braune S; Dieterle L; Forth B; Kortland LM; Lang M; Peckmann T; Schöffski O; Sigel KO; Rosenow F Epilepsy Behav; 2016 Nov; 64(Pt A):75-82. PubMed ID: 27732920 [TBL] [Abstract][Full Text] [Related]
22. Economic burden of epilepsy in a developing country: a retrospective cost analysis in China. Hong Z; Qu B; Wu XT; Yang TH; Zhang Q; Zhou D Epilepsia; 2009 Oct; 50(10):2192-8. PubMed ID: 19583782 [TBL] [Abstract][Full Text] [Related]
23. Health care cost associated with the use of enzyme-inducing and non-enzyme-active antiepileptic drugs in the UK: a long-term retrospective matched cohort study. Borghs S; Thieffry S; Noack-Rink M; Dedeken P; Hong LS; Byram L; Logan J; Chan J; Kiri V BMC Neurol; 2017 Mar; 17(1):59. PubMed ID: 28335764 [TBL] [Abstract][Full Text] [Related]
24. Report of the International League Against Epilepsy Commission on economic aspects of epilepsy. Beran RG; Pachlatko C Epilepsia; 1996 May; 37(5):506-8. PubMed ID: 8617183 [No Abstract] [Full Text] [Related]
25. Disease management programs target the high cost of epilepsy. Healthc Demand Dis Manag; 1997 Sep; 3(9):135-7. PubMed ID: 10174913 [TBL] [Abstract][Full Text] [Related]
26. Epilepsy control in the 21st century: leave no child behind. Pal DK Epilepsia; 2003 Mar; 44(3):273-5. PubMed ID: 12614380 [No Abstract] [Full Text] [Related]
27. The new generation of antiepileptic drugs: unresolved questions. Graves NM; Gidal BE; Gilliam FG Ann Pharmacother; 1998 Nov; 32(11):1239-43. PubMed ID: 9825094 [No Abstract] [Full Text] [Related]
28. [The direct cost of epilepsy in Cuba. A study in outpatients]. González-Pal S; Quintana Mendoza J; Román López JR; Fernández-Pérez JE Rev Neurol; 2005 Sep 16-30; 41(6):379-81. PubMed ID: 16163661 [No Abstract] [Full Text] [Related]
29. Response to "A graded system to categorize drug-resistant epilepsy". Agadi S; Riviello JJ; Quach MM Epilepsia; 2011 Mar; 52(3):653-4. PubMed ID: 21395572 [No Abstract] [Full Text] [Related]
30. Estimating the cost of epilepsy in Europe: a review with economic modeling. Pugliatti M; Beghi E; Forsgren L; Ekman M; Sobocki P Epilepsia; 2007 Dec; 48(12):2224-33. PubMed ID: 18088267 [TBL] [Abstract][Full Text] [Related]
31. Prevalence and cost of nonadherence to antiepileptic drugs in elderly patients with epilepsy. Ettinger AB; Manjunath R; Candrilli SD; Davis KL Epilepsy Behav; 2009 Feb; 14(2):324-9. PubMed ID: 19028602 [TBL] [Abstract][Full Text] [Related]
32. Uptake and costs of care for epilepsy: findings from a U.K. regional study. Jacoby A; Buck D; Baker G; McNamee P; Graham-Jones S; Chadwick D Epilepsia; 1998 Jul; 39(7):776-86. PubMed ID: 9670907 [TBL] [Abstract][Full Text] [Related]
34. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 - A ten-year overview. Willems LM; Richter S; Watermann N; Bauer S; Klein KM; Reese JP; Schöffski O; Hamer HM; Knake S; Rosenow F; Strzelczyk A Epilepsy Behav; 2018 Jun; 83():28-35. PubMed ID: 29649671 [TBL] [Abstract][Full Text] [Related]